Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.
Among the most prevalent of mental illnesses, depression is increasing in incidence in the Western world. It presents with a wide variety of symptoms that involve both the CNS and the periphery. Multiple pharmacological observations led to the development of the monoamine theory as a biological basis for depression, according to which diminished neurotransmission within the CNS, including that of the dopamine, noradrenaline (norepinephrine) and serotonin systems, is the leading cause of the disorder. Current conventional pharmacological antidepressant therapies, using selective monoamine reuptake inhibitors, tricyclic antidepressants and monoamine oxidase inhibitors, aim to enhance monoaminergic neurotransmission. However, the use of these agents presents severe disadvantages, including a delay in the alleviation of depressive symptoms, significant adverse effects and high frequencies of non-responding patients. Neuroendocrinological data of recent decades reveal that depression and anxiety disorders may occur simultaneously due to hypothalamus-pituitary-adrenal (HPA) axis hyperactivity. As a result, the stress-diathesis model was developed, which attempts to associate genetic and environmental influences in the aetiology of depression. The amygdala and the hippocampus control the activity of the HPA axis in a counter-balancing way, and a plethora of regulatory neuropeptide signalling pathways are involved. Intervention at these molecular targets may lead to alternative antidepressant therapeutic solutions that are expected to overcome the limitations of existing antidepressants. This prospect is based on preclinical evidence from pharmacological and genetic modifications of the action of neuropeptides such as corticotropin-releasing factor, substance P, galanin, vasopressin and neuropeptide Y. The recent synthesis of orally potent non-peptide micromolecules that can selectively bind to various neuropeptide receptors permits the onset of clinical trials to evaluate their efficacy against depression.
Paschos
Konstantinos A
KA
Laboratory of Pharmacology, School of Medicine, Democritus University of Thrace (DUTH), Alexandroupolis 68100, Thrace, Greece.
Veletza
Stavroula
S
Chatzaki
Ekaterini
E
D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018013:Receptors, Neuropeptide / Q000378:metabolism; D017480:Receptors, sigma / Q000378:metabolism
D000928:Antidepressive Agents; D018013:Receptors, Neuropeptide; D017480:Receptors, sigma
Neuropeptides. 2005 Jun;39(3):143-6
15944002
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10470-5
15240875
Curr Top Med Chem. 2008;8(6):506-20
18397172
Neuropharmacology. 2002 Dec;43(7):1165-72
12504923
Mol Pharmacol. 1992 Sep;42(3):458-63
1383685
Eur Neuropsychopharmacol. 2007 Jan;17(1):64-9
16624535
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6079-84
10823952
Cell Mol Life Sci. 2008 Jun;65(12):1854-63
18500640
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1333-8
12502022
Neuropharmacology. 1995 Dec;34(12):1697-9
8788968
Biol Psychiatry. 2006 Apr 1;59(7):594-602
16197926
Neurosci Res. 2000 Aug;37(4):307-14
10958979
Curr Pharm Des. 2005;11(12):1549-59
15892661
Eur J Pharmacol. 2004 Sep 19;499(1-2):135-46
15363960
Neurosci Biobehav Rev. 2002 May;26(3):259-83
12034130
Neuropsychopharmacology. 2002 Aug;27(2):194-202
12093593
Life Sci. 2006 Jan 25;78(9):909-19
16122764
Neuropsychopharmacology. 2004 Jan;29(1):1-14
12942143
J Clin Psychiatry. 2000;61 Suppl 6:4-6
10775017
Genes Brain Behav. 2008 Jul;7(5):532-42
18221379
Neuropeptides. 2005 Jun;39(3):293-8
15944025
J Psychiatr Res. 2003 Nov-Dec;37(6):525-33
14563384
Trends Neurosci. 1999 Jan;22(1):25-30
10088996
J Pharmacol Exp Ther. 1976 Jun;197(3):517-32
945347
Amino Acids. 2006 Oct;31(3):251-72
16820980
Pharmacol Rev. 1998 Mar;50(1):143-50
9549761
J Psychiatr Res. 2004 Mar-Apr;38(2):113-21
14757324
Neuropharmacology. 2001 Jul;41(1):138-49
11445194
J Biol Chem. 1985 Feb 10;260(3):1501-7
2578461
Peptides. 2007 Feb;28(2):326-33
17196302
Acta Neurochir Suppl (Wien). 1990;47:86-9
2407060
Pol J Pharmacol. 2002 Nov-Dec;54(6):699-702
12866727
Psychopharmacology (Berl). 2005 Mar;178(2-3):276-85
15365683
Behav Brain Res. 2003 May 15;141(2):251-5
12742262
J Psychiatr Res. 2000 May-Jun;34(3):171-81
10867111
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5
11959912
Neuropsychopharmacology. 2002 Sep;27(3):371-9
12225694
Br J Psychiatry. 1991 Jan;158:59-63
1673078
Int J Clin Pract. 2007 Dec;61(12):2030-40
17944926
Peptides. 2001 May;22(5):835-44
11337098
Pharmacol Rev. 1994 Dec;46(4):551-99
7534932
Can J Psychiatry. 1997 May;42(4):367-77
9161761
J Clin Psychiatry. 2004 Apr;65(4):492-9
15119911
Circ Res. 1988 Oct;63(4):812-20
2458861
Pharmacol Rep. 2006 Jul-Aug;58(4):493-500
16963794
J Pharmacol Exp Ther. 2001 Sep;298(3):1269-79
11504830
Biol Psychiatry. 1989 Feb 1;25(3):355-9
2536563
Am J Psychiatry. 1987 Jul;144(7):873-7
3496802
Exp Neurol. 2008 Mar;210(1):128-36
18035354
Neuropsychopharmacology. 2002 May;26(5):615-24
11927186
Nature. 1999 Aug 19;400(6746):766-8
10466725
Science. 1984 Dec 14;226(4680):1342-4
6334362
Eur J Neurosci. 2003 Jul;18(1):143-8
12859347
J Pharmacol Sci. 2005 Mar;97(3):317-36
15750289
J Biol Chem. 1998 Sep 4;273(36):23321-6
9722565
Eur J Pharmacol. 1993 Nov 30;250(1):R5-6
8119305
J Med Chem. 2000 Jan 27;43(2):177-89
10649973
Neuropsychopharmacology. 2003 Jan;28(1):140-7
12496950
Therapie. 2004 Jan-Feb;59(1):5-12
15199661
Eur J Pharmacol. 2000 Jun 16;398(2):239-46
10854835
Pharmacol Biochem Behav. 2006 Apr;83(4):533-9
16624395
Biol Psychiatry. 2006 Oct 15;60(8):892-5
16499879
Trends Pharmacol Sci. 2000 Mar;21(3):109-17
10689365
Biochem Biophys Res Commun. 1987 Nov 13;148(3):1208-14
3318828
J Comp Neurol. 2001 May 28;434(2):158-85
11331523
Am J Psychiatry. 2006 Apr;163(4):637-43
16585438
Biol Psychiatry. 2005 Jul 15;58(2):132-42
16038684
J Comp Neurol. 1992 May 22;319(4):479-500
1377713
Baillieres Clin Endocrinol Metab. 1996 Jan;10(1):75-96
8734452
Neuropsychopharmacology. 2004 Apr;29(4):777-84
14702025
N Engl J Med. 2008 Jan 3;358(1):55-68
18172175
Pharmacol Biochem Behav. 2005 Sep;82(1):223-7
16181667
Mol Psychiatry. 2001 Sep;6(5):540-6
11526468
Trends Pharmacol Sci. 1992 Mar;13(3):85-6
1315463
Neuropsychopharmacology. 2007 Sep;32(9):1941-9
17287823
J Clin Psychiatry. 2005;66 Suppl 7:5-13
16124836
Trends Pharmacol Sci. 2003 Nov;24(11):580-8
14607081
Eur J Pharmacol. 1996 Sep 5;311(1):7-14
8884230
Nature. 1995 Nov 16;378(6554):287-92
7477349
Eur J Pharmacol. 2008 Apr 7;583(2-3):340-9
18255056
Curr Pharm Des. 2005;11(2):205-25
15638758
Nat Rev Neurosci. 2005 Jun;6(6):463-75
15891777
Am J Obstet Gynecol. 2006 Jul;195(1):288-95
16626608
Neurosci Biobehav Rev. 2007;31(1):89-102
16934871
Nat Genet. 2000 Apr;24(4):410-4
10742108
Paediatr Perinat Epidemiol. 2001 Jul;15 Suppl 2:124-35
11520405
Neurosci Lett. 2000 Apr 21;284(1-2):89-92
10771169
J Comp Neurol. 2001 Sep 3;437(4):496-504
11503148
J Pharmacol Exp Ther. 2001 Nov;299(2):449-58
11602654
Neuropeptides. 1993 Jun;24(6):317-9
7688872
J Neurosci. 1995 Jun;15(6):4250-8
7790909
Life Sci. 1997;60(18):1523-33
9126874
Neurosci Bull. 2008 Jun;24(3):155-9
18500388
Mol Psychiatry. 2004 Mar;9(3):287-92
15094789
J Neurol Neurosurg Psychiatry. 1985 Jan;48(1):50-7
3973621
Behav Pharmacol. 2001 Nov;12(6-7):497-508
11742144
Curr Med Chem. 2006;13(23):2751-60
17073626
Can J Physiol Pharmacol. 2002 May;80(5):489-94
12056558
Mol Pharmacol. 2002 Dec;62(6):1314-20
12435798
Br J Pharmacol. 2007 Jul;151(6):737-48
17471183
Neuroreport. 2002 Jul 2;13(9):1223-7
12151774
Peptides. 1999;20(3):367-72
10447095
Brain Res. 2001 Oct 12;915(2):170-5
11595206
Eur J Neurosci. 1998 Jul;10(7):2337-45
9749762
J Manag Care Pharm. 2007 Jul;13(6 Suppl A):S2-7
17672818
Neurosci Lett. 2006 Sep 11;405(1-2):111-5
16854525
Pharmacol Biochem Behav. 2002 Mar;71(3):419-23
11830176
Gynecol Endocrinol. 2001 Apr;15(2):98-102
11379015
Mol Psychiatry. 2004 Mar;9(3):278-86, 224
14699428
Pharmacol Biochem Behav. 1998 Nov;61(3):247-52
9768559
Pharmacol Rev. 1990 Dec;42(4):355-402
1964225
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7570-5
11416224
Eur Neuropsychopharmacol. 1999 Mar;9(3):205-11
10208289
Arch Gen Psychiatry. 2008 Feb;65(2):190-200
18250257
J Neurosci. 1995 Oct;15(10):6340-50
7472399
J Pharmacol Exp Ther. 2004 Nov;311(2):427-40
15297468
Psychopharmacol Bull. 2002 Summer;36 Suppl 2:6-23
12490820
Endocrinology. 2003 Jun;144(6):2580-7
12746321
Biol Psychiatry. 2006 Feb 1;59(3):216-23
16248986
J Neurochem. 2004 Apr;89(1):54-63
15030389
Braz J Psychiatry. 2003 Oct;25(4):231-8
15328550
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):283-99
11263757
Pharmacopsychiatry. 2004 Nov;37 Suppl 3:S214-20
15547788
Schizophr Bull. 2003;29(4):671-92
14989406
Biol Psychiatry. 2005 Apr 15;57(8):935-7
15820716
Curr Drug Targets CNS Neurol Disord. 2003 Jun;2(3):191-200
12769799
Neuropeptides. 2000 Oct;34(5):255
11049729
Curr Pharm Des. 2006;12(30):3857-76
17073684
Cell Mol Biol (Noisy-le-grand). 1999 Nov;45(7):1083-92
10644013
J Psychiatr Res. 2005 Mar;39(2):173-7
15589565
Endocrinology. 1994 Oct;135(4):1511-28
7925112
Neuropsychopharmacology. 2005 Sep;30(9):1589-97
15770236
Psychol Med. 2000 Jan;30(1):219-23
10722192
Neuropeptides. 2007 Oct;41(5):307-20
17637475
Neuropsychopharmacology. 2004 Feb;29(2):385-92
14666114
Neuropeptides. 2001 Apr;35(2):82-91
11384203
Neuropsychopharmacology. 1997 Oct;17(4):284-92
9326754
Mol Cell Endocrinol. 1999 Dec 20;158(1-2):55-63
10630405
J Psychiatr Res. 2007 Oct;41(7):553-60
17023001
Life Sci. 2002 Nov 8;71(25):2921-37
12384178
Behav Brain Res. 2008 May 16;189(1):9-16
18258314
Behav Brain Res. 1994 Jul 29;63(1):81-8
7524534
Neuroscience. 1998 Nov;87(1):79-94
9722143
Biol Psychiatry. 1997 Oct 15;42(8):744-7
9325570
Dev Psychopathol. 2001 Summer;13(3):419-49
11523842
J Neurochem. 1999 Aug;73(2):641-6
10428060
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2843-8
11226328
Arch Gen Psychiatry. 2001 Jul;58(7):655-62
11448372
Pharmacol Ther. 1999 Apr;82(1):1-61
10341356
Eur Neuropsychopharmacol. 2002 Oct;12(5):489-94
12208567
Neurosci Biobehav Rev. 2001 Dec;25(7-8):619-26
11801287
J Clin Endocrinol Metab. 1995 Jan;80(1):185-9
7829610
J Pharmacol Exp Ther. 2003 Feb;304(2):874-80
12538845
Health Qual Life Outcomes. 2006 Jan 18;4:2
16420706
J Clin Endocrinol Metab. 2002 Apr;87(4):1646-53
11932296
Science. 1998 Sep 11;281(5383):1640-5
9733503
Neuropsychopharmacology. 2005 Jan;30(1):35-42
15367924
Neuromolecular Med. 2005;7(1-2):157-80
16052044
Neuropeptides. 2004 Aug;38(4):189-200
15337371
J Psychiatr Res. 2004 Mar-Apr;38(2):129-36
14757326
Neuropeptides. 1999 Apr;33(2):181-8
10657489
Life Sci. 1992;50(15):PL101-6
1313515
Ann N Y Acad Sci. 1988;537:273-91
3059929
Neuroendocrinology. 1990 Mar;51(3):328-36
2157997
Pharmacol Biochem Behav. 2008 Sep;90(3):463-9
18495229
Recent Pat CNS Drug Discov. 2008 Jun;3(2):77-93
18537767
Am J Psychiatry. 2002 Oct;159(10):1675-81
12359672
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94
16287967
Neuropharmacology. 2003 Feb;44(2):206-13
12623219
Life Sci. 2001 Jun 1;69(2):133-42
11441903
Therapie. 2002 Jul-Aug;57(4):385-96
12422559
Clin Pharmacol Ther. 2003 Mar;73(3):170-7
12621382
Eur J Pharmacol. 2005 Jan 10;507(1-3):99-105
15659299
Amino Acids. 2006 Oct;31(3):215-30
16738800
Eur Neuropsychopharmacol. 2008 Oct;18(10):729-50
18657401
J Psychiatr Res. 1999 Sep-Oct;33(5):363-70
10504004
Neuropeptides. 2008 Aug;42(4):387-97
18554714
Eur J Endocrinol. 2003 Aug;149(2):79-90
12887283
Ann N Y Acad Sci. 1998 Dec 21;863:459-65
9928199
Nat Neurosci. 1998 May;1(1):69-73
10195112
Curr Opin Neurobiol. 2000 Apr;10(2):211-8
10753802
Psychopharmacology (Berl). 2006 Aug;187(2):237-44
16779555
Mol Cell Biol. 2005 Jun;25(11):4804-11
15899880
Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):113-21
15078186
Drug News Perspect. 1998 Oct;11(8):458-68
15616674
Front Neuroendocrinol. 2004 Sep-Dec;25(3-4):132-49
15589266
Eur Neuropsychopharmacol. 2007 Nov;17(11):708-16
17376658
Arch Gen Psychiatry. 1996 Feb;53(2):137-43
8629889
Pharmacol Biochem Behav. 2007 Jan;86(1):8-20
17257664
Eur J Pharmacol. 2008 Apr 7;583(2-3):350-7
18272149
Exp Clin Psychopharmacol. 2007 Dec;15(6):519-28
18179304
Trends Neurosci. 2008 Sep;31(9):464-8
18675469
Eur J Pharmacol. 1996 Jun 13;306(1-3):271-9
8813641
Ann N Y Acad Sci. 1998 Dec 21;863:364-82
9928183
J Psychopharmacol. 2008 Aug;22(6):691-6
18308813
Neuropharmacology. 2001 Dec;41(8):976-88
11747902
JAMA. 2003 Jun 18;289(23):3095-105
12813115